PegBio Signs R&D Collaboration with SN BioScience to Pair Three Next-Generation Peptide Candidates with SN BioScience’s SNA Long-Acting Delivery Platform for Obesity and Metabolic Diseases 

PegBio Co., Ltd. (HKG: 2565) has entered into a Material Transfer Agreement (MTA) with South Korean biotechnology company SN BioScience, Inc. to conduct joint research and development on three of PegBio’s independently developed innovative peptide drug candidates for metabolic diseases. The collaboration will apply SN BioScience’s proprietary SNA long-acting drug delivery platform to PegBio’s candidates, including APGP6, to evaluate the potential of next-generation long-acting delivery to enhance the candidates’ pharmacokinetic profiles, tolerability, dosing convenience, and overall product differentiation. 

https://flcube.com/?p=78531